31733-60-5Relevant academic research and scientific papers
Pharmaceutical composition and method of treating cancer
-
Page/Page column 45-46, (2020/12/07)
Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
Catalytic antibodies with acyl-transfer capabilities: Mechanistic and kinetic investigations
Janda, Kim D.,Ashley, Jon A.,Jones, Teresa M.,McLeod, Donald A.,Schloeder, Diane M.,Weinhouse, Michael I.,Lerner, Richard A.,Gibbs, Richard A.,Benkovic, Patricia A.,Hilhorst, Riet,Benkovic, Stephen J.
, p. 291 - 297 (2007/10/02)
Antibodies have been shown to catalyze acyl-transfer reactions. The processes by which they perform such tasks have often been postulated but largely remain unknown. An extended study is presented on three different monoclonal antibodies that catalyze the
Anticonvulsant activity of some 4-aminophenylacetamides
Clark,Davenport
, p. 18 - 20 (2007/10/02)
A series of 4-aminophenylacetamides was prepared and evaluated for anticonsulvant activity. These compounds were prepared during studies designed to determine the relationship between benzamide-like compounds and anticonsulvant effects. Unlike benzamides, these phenylacetamides have a methylene group between the aromatic ring and the amide carbonyl. Consequently, formal conjugation is lost, and the number of conformational degrees of freedom has increased. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazol, and in the rotorod assay for neurologic deficit. The more active and selective anticonsulvants prepared in this study were those having an additional aromatic ring as part of the substituent on the amide nitrogen. Compound 16, the 4-aminophenylacetamide derived from 2,6-dimethylaniline, was the most potent compound observed (ED50 = 50.50 mg/kg against electroshock-induced convulsions and ED50 = 93.20 mg/kg against pentylenetetrazol-induced convulsions).
